America’s obesity crisis extends beyond humans — studies suggest that around 60% of dogs and cats nationwide are overweight.

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.

Pedersen and Maggie Fick COPENHAGEN (Reuters) -As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the ...

Many Mounjaro users have considered making the swap after Eli Lilly announced prices would be increasing in the UK by 170 ...

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...

Taking meds to lose weight has been surging among Americans. While these drugs are safe, they have one drawback, they can also cause muscle mass loss.

The outgoing chief executive of Novo Nordisk has revealed plans to ramp-up cost cutting 'efficiencies' across the business, as the drugmaker battles to fend off rivals.

The weight loss injectable Ozempic has faced several lawsuits in 2025 from people who had a negative experience with the ...

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...